Brilacidin Brilacidin by Innovation Pharmaceu
Post# of 714
(Total Views: 230)
Posted On: 04/15/2020 1:42:29 PM
Brilacidin
Brilacidin by Innovation Pharmaceuticals is a candidate being evaluated as a potential treatment for coronavirus. Brilacidin has shown antibacterial, anti-inflammatory and immunomodulatory properties in several clinical trials.156 Review articles suggest that immunomodulators, like Brilacidin could potentially act synergistically when combined with antivirals.157,158
Brilacidin is my top pick of all the drugs. Why? antibacterial, anti-inflammatory and immunomodulatory.
Reading through the article this is an excerpt...
NICE is currently reviewing ibuprofen and other non-steroidal anti-inflammatory drugs used to reduce temperature and ease flu-like symptoms, as well as angiotensin converting enzyme (ACE) inhibitors used to treat high blood pressure or heart failure. NICE are working with the Medicines and Healthcare products Regulatory Agency to facilitate rapid review of information and advice on the safety and efficacy of treatments for COVID-19.
https://sph.nus.edu.sg/wp-content/uploads/202...13-Apr.pdf
Brilacidin is currently waiting on lung tissue data.
WAKEFIELD, MA – April 6, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB: IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today the Company is engaged in discussions with health care provider networks and hospitals both in the United States and Europe regarding options to rapidly advance Brilacidin testing into human trials to evaluate its potential as a novel coronavirus (COVID-19) therapeutic.
Their interest in Brilacidin as a treatment for COVID-19 and associated complications is based on the drug’s promising antiviral activity against SARS-CoV-2, as supported in preliminary testing conducted in a monkey epithelial cell line, and its established anti-inflammatory and antimicrobial properties —a potential 3-in-1 treatment combination. In advance of potential clinical testing, the Company is investigating procurement of appropriate drug supply (i.e., manufacture of intravenous drug product), and preparing for engagement with regulatory authorities. There can be no assurance that any Brilacidin for COVID-19 clinical trial will commence.
Concurrently, laboratory testing of Brilacidin against SARS-CoV-2, the novel coronavirus responsible for COVID-19, will continue. This is based on recommendations made by the lead researcher at one of the U.S. Regional Biocontainment Laboratories (RBLs) who performed preliminary testing of Brilacidin. Results were characterized as “extremely encouraging.” Immediate next steps include conducting studies in human lung cells, exploring dosing and evaluating the drug’s effect on the viral envelope.
http://www.ipharminc.com/press-release/2020/4...t-covid-19
Quite possible brilacidin could be used in combo with another treatment.
Brilacidin by Innovation Pharmaceuticals is a candidate being evaluated as a potential treatment for coronavirus. Brilacidin has shown antibacterial, anti-inflammatory and immunomodulatory properties in several clinical trials.156 Review articles suggest that immunomodulators, like Brilacidin could potentially act synergistically when combined with antivirals.157,158
Brilacidin is my top pick of all the drugs. Why? antibacterial, anti-inflammatory and immunomodulatory.
Reading through the article this is an excerpt...
NICE is currently reviewing ibuprofen and other non-steroidal anti-inflammatory drugs used to reduce temperature and ease flu-like symptoms, as well as angiotensin converting enzyme (ACE) inhibitors used to treat high blood pressure or heart failure. NICE are working with the Medicines and Healthcare products Regulatory Agency to facilitate rapid review of information and advice on the safety and efficacy of treatments for COVID-19.
https://sph.nus.edu.sg/wp-content/uploads/202...13-Apr.pdf
Brilacidin is currently waiting on lung tissue data.
WAKEFIELD, MA – April 6, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB: IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today the Company is engaged in discussions with health care provider networks and hospitals both in the United States and Europe regarding options to rapidly advance Brilacidin testing into human trials to evaluate its potential as a novel coronavirus (COVID-19) therapeutic.
Their interest in Brilacidin as a treatment for COVID-19 and associated complications is based on the drug’s promising antiviral activity against SARS-CoV-2, as supported in preliminary testing conducted in a monkey epithelial cell line, and its established anti-inflammatory and antimicrobial properties —a potential 3-in-1 treatment combination. In advance of potential clinical testing, the Company is investigating procurement of appropriate drug supply (i.e., manufacture of intravenous drug product), and preparing for engagement with regulatory authorities. There can be no assurance that any Brilacidin for COVID-19 clinical trial will commence.
Concurrently, laboratory testing of Brilacidin against SARS-CoV-2, the novel coronavirus responsible for COVID-19, will continue. This is based on recommendations made by the lead researcher at one of the U.S. Regional Biocontainment Laboratories (RBLs) who performed preliminary testing of Brilacidin. Results were characterized as “extremely encouraging.” Immediate next steps include conducting studies in human lung cells, exploring dosing and evaluating the drug’s effect on the viral envelope.
http://www.ipharminc.com/press-release/2020/4...t-covid-19
Quite possible brilacidin could be used in combo with another treatment.
(1)
(0)Scroll down for more posts ▼